A pilot study of high‐dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram‐positive bacteria

Background:  Methicillin‐susceptible and ‐resistant (MRSA) Staphylococcus aureus are significant causes of complicated skin and skin structure infections (cSSSI). The bactericidal antibiotic daptomycin is approved for gram‐positive cSSSI at 4 mg/kg/day for 7–14 days, but the optimal dose level and duration of therapy have not been firmly established. This pilot study evaluated the efficacy and safety of daptomycin at 10 mg/kg every 24 h for 4 days [high‐dose short duration (HDSD) regimen] vs. standard of care therapy with vancomycin or semi‐synthetic penicillin for the treatment of cSSSI.

[1]  Warren E. Rose,et al.  Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations , 2007, Antimicrobial Agents and Chemotherapy.

[2]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[3]  L. Friedrich,et al.  Daptomycin in the treatment of bacteremia. , 2007, The American journal of medicine.

[4]  G. M. Allan,et al.  Evidence-based approach to abscess management. , 2007, Canadian family physician Medecin de famille canadien.

[5]  D. Levine,et al.  Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. , 2007, The American journal of medicine.

[6]  Naci Oner,et al.  The comparison of single-dose ceftriaxone, five-day azithromycin, and ten-day amoxicillin/clavulanate for the treatment of children with acute otitis media. , 2007, The Turkish journal of pediatrics.

[7]  D. Moore,et al.  Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. , 2007, The American journal of medicine.

[8]  G. Kaatz,et al.  Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. , 2007, The Journal of antimicrobial chemotherapy.

[9]  K. Lindfield,et al.  Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections* , 2007, Current medical research and opinion.

[10]  Xilin Zhao,et al.  Mutant selection window hypothesis updated. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Mortin,et al.  Rapid Bactericidal Activity of Daptomycin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Peritonitis in Mice as Measured with Bioluminescent Bacteria , 2007, Antimicrobial Agents and Chemotherapy.

[12]  M. Zhan,et al.  Comparison of Mortality Risk Associated With Bacteremia Due to Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus , 2007, Infection Control & Hospital Epidemiology.

[13]  S. Zinner,et al.  Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. , 2006, The Journal of antimicrobial chemotherapy.

[14]  S. Yankelev,et al.  Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[15]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[16]  Vance G Fowler,et al.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.

[17]  G. Drusano,et al.  The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  R. Gaynes,et al.  Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  S. Cosgrove,et al.  The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges , 2005, Infection Control & Hospital Epidemiology.

[20]  E. Armstrong,et al.  Clinical and Economic Analysis of Methicillin-Susceptible and -Resistant Staphylococcus aureus Infections , 2004, The Annals of pharmacotherapy.

[21]  John S. Bradley,et al.  Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy , 2004 .

[22]  R. Arbeit,et al.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Mejias,et al.  Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus , 2004, The Pediatric infectious disease journal.

[24]  Donald R Graham,et al.  Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Ronald N. Jones,et al.  Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). , 2003, Diagnostic microbiology and infectious disease.

[26]  S. Cosgrove,et al.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Alder,et al.  Daptomycin: a novel lipopeptide antibiotic , 2002 .

[28]  Steven D. Brown,et al.  In vitro bactericidal activity of daptomycin against staphylococci. , 2002, The Journal of antimicrobial chemotherapy.

[29]  M. Whitby,et al.  Risk of death from methicillin‐resistant Staphylococcus aureus bacteraemia: a meta‐analysis , 2001, The Medical journal of Australia.

[30]  C Peña,et al.  Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. , 2001, JAMA.

[31]  R N Jones,et al.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R. Akins,et al.  Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-ResistantStaphylococcus aureus, Vancomycin-ResistantEnterococcus faecium, and Methicillin-ResistantStaphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial V , 2001, Antimicrobial Agents and Chemotherapy.

[33]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[34]  I S Chan,et al.  Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions , 1999, Biometrics.

[35]  R. Nichols.  Optimal treatment of complicated skin and skin structure infections. , 1999, The Journal of antimicrobial chemotherapy.

[36]  G. Drusano,et al.  Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity , 1999, Antimicrobial Agents and Chemotherapy.

[37]  A. Conde.  Staphylococcus aureus infections. , 1998, The New England journal of medicine.

[38]  D. Nicolau,et al.  Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. , 1997, The Journal of antimicrobial chemotherapy.

[39]  M. Barclay,et al.  What is the Evidence for Once-Daily Aminoglycoside Therapy? , 1994, Clinical pharmacokinetics.

[40]  H. Morton,et al.  Staphylococcus aureus , 1948 .